Skip to main content
Premium Trial:

Request an Annual Quote

Cynvenio Biosystems PD-L1 Expression Assay

Cynvenio Biosystems has launched its second-generation PD-L1 expression test. The blood test has improved analytic performance compared to the first-generation test, enabling highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer cells recovered from blood. Cynvenio is offering the test from its CLIA/CAP laboratory in California with a three- to seven-day turnaround time. The test is also available to all Cynvenio customers running its LiquidBiopsy platform and workflow, the company said.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.